Related Experiment Videos
[Heparin-induced thrombocytopenia type II].
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|November 7, 1999
Summary
Heparin-induced thrombocytopenia type II (HIT type II) is a serious complication of heparin therapy. Prompt recognition and cessation of heparin, along with alternative anticoagulation, are crucial for managing HIT type II and preventing thromboembolic events.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Context:
- Heparin-induced thrombocytopenia type II (HIT type II) is a life-threatening immune-mediated adverse drug reaction.
- Affecting 1-3% of patients on heparin, HIT type II carries a significant mortality (20%) and disability (20%) risk.
- Thrombocytopenia in HIT type II often precedes severe venous or arterial thromboembolic complications.
Purpose:
- To outline the clinical relevance and diagnostic considerations for HIT type II.
- To discuss immediate management strategies, including heparin cessation and alternative anticoagulation.
- To review diagnostic laboratory testing and prophylaxis recommendations for HIT type II.
Summary:
- HIT type II necessitates immediate cessation of heparin and initiation of alternative anticoagulation.
- Diagnosis confirmation involves laboratory testing, including cross-reactivity assessment with danaparoid.
- Management and prophylaxis strategies are critical to mitigate the high morbidity and mortality associated with HIT type II.
Impact:
- Early detection and appropriate management of HIT type II can significantly reduce mortality and long-term disability.
- Implementing strict prophylaxis guidelines, such as judicious use of low-molecular-weight heparin (LMWH), is essential.
- Understanding HIT type II pathophysiology guides therapeutic decisions and improves patient outcomes in heparin-treated individuals.